Year: 2022
Language: English
Author(s): World Federation of Hemophilia
Ensuring patient safety is of paramount importance during the clinical trial process. There are many levels of study approval and monitoring to protect the safety of participants in clinical trials, and a system in place for collecting and reporting safety outcomes during a study.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
This handbook contains basic information about clinical trials for hemophilia. The WFH does not engage in the practice of medicine
Participants in clinical trials and health care providers have different roles throughout the clinical trial process. It is important that
For people considering participation in a clinical trial, it is extremely important to learn as much as possible about the
For a drug to become a treatment that doctors can prescribe, it must first be tested in a series of
Follow the progress of hemophilia gene therapy clinicals with the WFH Gene Therapy for Hemophilia Pipeline tool to track clinical
Clinical trials must be designed to fulfill high scientific and ethical standards. This monograph reviews the basic principles of good
